Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
105M
-
Number of holders
-
196
-
Total 13F shares, excl. options
-
98.9M
-
Shares change
-
-2.9M
-
Total reported value, excl. options
-
$2.64B
-
Value change
-
-$77.6M
-
Put/Call ratio
-
0.27
-
Number of buys
-
103
-
Number of sells
-
-80
-
Price
-
$26.70
Significant Holders of Edgewise Therapeutics, Inc. - Common Stock, par value $0.0001 per share (EWTX) as of Q4 2024
231 filings reported holding EWTX - Edgewise Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q4 2024.
Edgewise Therapeutics, Inc. - Common Stock, par value $0.0001 per share (EWTX) has 196 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 98.9M shares
of 105M outstanding shares and own 93.89% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (15M shares), RA CAPITAL MANAGEMENT, L.P. (8.91M shares), BlackRock, Inc. (6.48M shares), BAKER BROS. ADVISORS LP (6.16M shares), Novo Holdings A/S (5M shares), JANUS HENDERSON GROUP PLC (4.98M shares), Paradigm Biocapital Advisors LP (4.49M shares), VANGUARD GROUP INC (4.47M shares), Cormorant Asset Management, LP (3.41M shares), and PERCEPTIVE ADVISORS LLC (2.69M shares).
This table shows the top 196 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.